DNLI July 18th Options Begin Trading - Nasdaq
8 hours ago • Google News
Denali Therapeutics Inc (DNLI)
US$ 21.43-7.71%
Price Chart
Key Statistics
Market Cap
$ 2.07B
P/E Ratio
0.00
Revenue (TTM)
$ 0
Volume
1.04M
52W High
$ 33.33
52W Low
$ 10.57
Dividend Yield
0.00%
Beta
1.49
Technicals
50-Day MA
14.4311
200-Day MA
21.9554
52 Week High
33.33
52 Week Low
10.57
About DNLI
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases.
Employees
443
Headquarters
South San Francisco, CA
CEO
Dr. Ryan J. Watts Ph.D.
Latest News
Top Gainers
Symbol/Name
LTP
% Chg
Top Losers
Symbol/Name
LTP
% Chg